CHARLOTTE, N.C. - TelAve -- Nufabrx, a leader in pain-relieving compression products, today announced an oversubscribed fundraising round led by Meltzer Capital, which has committed $5 million towards continued growth and innovation.

The strong investor interest has resulted in the round exceeding its initial target, reflecting growing confidence in Nufabrx's product portfolio and rapidly expanding market opportunity. The funding will be used to support the company's continued growth, including product innovation, distribution expansion, and increased brand awareness.

"Meltzer Capital is thrilled to lead the financing round in Nufabrx, which will enable millions of people around the world to gain access to relief from various forms of pain without using opioids," said David Meltzer, Founder and CEO of Meltzer Capital. "We believe in Nufabrx's mission, which aligns perfectly with our objective to partner with organizations that have bold ideas that can leave a lasting impact."

Nufabrx develops patented, FDA-registered compression products that deliver capsaicin, a pain-relieving ingredient, directly to the skin to provide a targeted, wearable solution for pain management and recovery. The company continues to see increased adoption as consumers seek convenient alternatives to traditional pain relief solutions.

More on TelAve News

• Aries Industries Streamlines Sewer Inspection Process With Introduction of the LETS Sidewinder
• Chronic Boss Awards Scholarships to Student Founders Living with Chronic Conditions
• Nest Finders Property Management Named #1 in Jacksonville and Ranked #99 Nationwide
• Nashville International Chopin Piano Competition Launches First Amateur Edition
• Market Value Enhancement From 2 Important New US Patents Issued for Strengthening Hair Enzyme Booster Technology to Caring Brands (NAS DAQ: CABR)

Meltzer Capital's leadership in the round brings both capital and strategic expertise as Nufabrx scales operations and advances its product portfolio across channels.

"This investment marks an important milestone for Nufabrx," said Glenn Normoyle, CEO of Nufabrx. "Meltzer Capital's $5 million commitment validates our technology and long-term vision. We're excited to build on this momentum as we continue to grow."

For more information on Nufabrx, please visit: https://nufabrx.com/pages/about-us

About Nufabrx: Nufabrx is an innovative company focused on the controlled delivery of pain-relieving medication (capsaicin) through compression products. Our products deliver consistent, therapeutic doses of capsaicin directly to the skin, eliminating the need for pills, creams, or sprays. Designed for durability, the capsaicin remain effective after multiple washes, providing unmatched convenience and reliability.